Cannabidiol

證據等級: L5

預測適應症: 10 個

Cannabidiol: From Epilepsy to Restless Legs Syndrome

Disclaimer: This report is intended for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.

One-Sentence Summary

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid internationally approved for treatment-resistant epilepsy (Dravet syndrome and Lennox-Gastaut syndrome), though it currently holds no marketing authorisation in Denmark. The TxGNN model predicts it may be effective for Restless Legs Syndrome (RLS), with a prediction score of 96.17% and 4 clinical trials registered — including one Phase 2 RCT directly targeting idiopathic RLS — providing a plausible mechanistic and emerging clinical basis for this direction.

Quick Overview

Item	Content
Original Indication	Epilepsy (Dravet syndrome / Lennox-Gastaut syndrome) — international approval; not currently registered in Denmark
Predicted New Indication	Restless Legs Syndrome
TxGNN Prediction Score	96.17%
Evidence Level	L2
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action (MOA) data was not available in the current evidence pack. Based on established pharmacological literature, CBD acts through multiple neuromodulatory targets: it modulates the endocannabinoid system (ECS) via CB1 and CB2 receptors without acting as a direct agonist, inhibits GABA and adenosine reuptake, activates TRPV1 channels, and antagonises GPR55. It is approved as Epidiolex/Epidyolex (EMA centralised authorisation) for seizure reduction in Dravet syndrome and Lennox-Gastaut syndrome.

Restless Legs Syndrome is a sensorimotor disorder whose core pathophysiology involves striatal dopaminergic dysfunction, impaired spinal inhibitory neurotransmission, iron metabolism disturbances, and heightened central hyperarousal. CBD’s potential relevance to RLS is mechanistically grounded: (1) the ECS directly modulates striatal dopamine release — the primary dysregulation in RLS; (2) GABA reuptake inhibition may reduce sensory dysaesthesia and periodic limb movements; (3) CB1 receptor-mediated spinal inhibitory signalling may attenuate the pathological urge-to-move; and (4) emerging preclinical evidence suggests ECS involvement in iron homeostasis, which intersects with the well-established iron-deficiency aetiology of RLS.

While the mechanistic pathway from epilepsy to RLS is not direct, both conditions share features of neurological hyperexcitability and disrupted inhibitory signalling. CBD’s broad neuromodulatory profile — particularly its dopaminergic and GABAergic activity — provides a pharmacologically plausible basis for the TxGNN prediction, with mechanistic plausibility rated moderate-to-high.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07224932	Phase 2	Not Yet Recruiting	60	Randomised, double-blind, placebo-controlled parallel RCT of high-CBD cannabis extract (BRC-002) specifically in idiopathic RLS patients; primary endpoint: tolerability and safety; start planned December 2025 — the only direct RLS trial in this dataset
NCT05092191	Phase 2	Recruiting	250	Cannabinoids vs current standard treatments for symptom relief in Multiple Sclerosis (Canada); RLS is a recognised MS comorbidity and included as a secondary symptom endpoint; results not yet available
NCT02818777	Phase 2	Completed	13	Double-blind, placebo-controlled crossover RCT of CBD (GWP42003) on tremor in Parkinson’s Disease; completed November 2017; small sample size limits statistical power, but crossover design enhances within-subject sensitivity
NCT03582137	Phase 2	Completed	74	Double-blind, placebo-controlled parallel RCT of CBD on motor symptoms in Parkinson’s Disease; primary endpoint: MDS-UPDRS Part III motor score; completed January 2022; largest completed CBD motor-disorder RCT in this dataset

Note: NCT02818777 and NCT03582137 are Parkinson’s Disease trials, not direct RLS trials. Their inclusion reflects mechanistic and phenotypic overlap between dopaminergic movement disorders; findings should not be directly extrapolated to idiopathic RLS populations.

Literature Evidence

Currently no RLS-specific literature is available in this evidence pack.

Denmark Market Information

Cannabidiol is currently not marketed in Denmark and holds no national or EMA centralised marketing authorisation registered in this dataset (0 licences). Danish healthcare professionals considering off-label use or research access should note the following:

Consideration	Detail
Epidyolex (EMA)	EMA centralised authorisation exists for Dravet syndrome/LGS; validity in Denmark subject to national reimbursement and import procedures
Access pathway	Named patient / hospital exemption application to Lægemiddelstyrelsen may be required
Regulatory contact	Lægemiddelstyrelsen — www.laegemiddelstyrelsen.dk

Safety Considerations

Specific safety data for this candidate is not currently available in this evidence pack — all safety fields are pending data retrieval. Please refer to the approved Summary of Product Characteristics (SmPC) for Epidiolex/Epidyolex for full safety information.

Clinically relevant safety signals from published literature and the SmPC include:

Hepatotoxicity: Elevated transaminases reported, particularly when co-administered with valproate — liver function monitoring required
CNS effects: Somnolence, fatigue, and sedation, especially at higher doses
Gastrointestinal: Decreased appetite, diarrhoea, and vomiting
Drug interactions: CBD is a CYP2C19 inhibitor and CYP3A4 substrate; DDI profiling was not returned in the current data pull and should be conducted prior to any clinical use

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN model assigns a high prediction score (96.17%), mechanistic plausibility is moderate-to-high, and the research landscape is actively evolving — a dedicated Phase 2 RLS RCT (NCT07224932) is registered and expected to provide direct efficacy and safety data. However, no completed trials have directly evaluated CBD in idiopathic RLS, and all completed Phase 2 RCTs in this dataset are Parkinson’s Disease studies. A “Proceed with Guardrails” decision is appropriate: the hypothesis is scientifically credible and worth advancing, but requires stronger direct evidence before clinical adoption.

To proceed, the following is needed:

Primary: Await and review results from NCT07224932 (direct RLS Phase 2 RCT; originally planned for completion February 2026 — confirm recruitment status)
Regulatory: Determine current EMA/Lægemiddelstyrelsen access pathway for CBD in Denmark; clarify whether Epidyolex centralised authorisation is recognised or requires separate national application
Safety: Retrieve full SmPC warnings, contraindications, and DDI profile for CBD (currently data gap); assess hepatotoxicity risk in RLS patient population
Positioning: Define CBD’s therapeutic role relative to established first-line RLS treatments (dopamine agonists: pramipexole, ropinirole; α₂δ ligands: gabapentin enacarbil, pregabalin) — adjunct vs. alternative
RLS subtype: Clarify evidence applicability to idiopathic vs. secondary (iron deficiency, renal, MS-associated) RLS subtypes, given the mechanistic intersection with iron metabolism
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.